newsfilter
← Latest News
GlobeNewswire·

Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital

Funding from second closing extends cash runway to mid-2025 to advance the company's HSC gene therapy portfolio through several potential value-creating milestones OTL-200 (MLD) BLA submission initiated and on track for